Martin J. Blaser

Martin J. Blaser holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University, where he also serves as Professor of Medicine and Pathology & Laboratory Medicine, and as Director of the Center for Advanced Biotechnology and Medicine.  Previously, he served as Chair of the Department of Medicine at New York University. A physician and microbiologist, Dr. Blaser has been studying the relationships we have with our persistently colonizing bacteria. His work over 30 years focused on Campylobacter species and Helicobacter pylori, which also are model systems for understanding the interactions of residential bacteria with their hosts. Over the last 20 years, he has also been actively studying the relationship of the human microbiome with health and important diseases including asthma and allergy, obesity, diabetes, neurological conditions, and cancer. Dr. Blaser has served as the advisor to many students, post-doctoral fellows, and junior faculty. He holds 28 U.S. patents and has authored over 600 original articles. He wrote Missing Microbes, a book targeted to general audiences, now translated into 20 languages.

Microbiome studies

B.A. Economics, University of Pennsylvania, 1969, M.D. New York University School of Medicine, 1973

Henry Rutgers Chair of the Human Microbiome

Professor
Departments of Medicine and Pathology & Laboratory Medicine
RBHS, Robert Wood Johnson Medical School

National Academy of Medicine

American Academy of Arts and Sciences

Oswald Avery Award

Alexander Fleming Award

Robert Koch Award

Microbiology Society (Great Britain) Prize Medal

Docteur honoris causa, University of Bordeaux, France

Professor of Medicine and Pathology & Laboratory Medicine, RWJMS

Professor of Epidemiology & Biostatistics, School of Public Health

Past Boards:

Presidential Advisory Council for Combating Antibiotic Resistant Bacteria – (PACCARB; founding Chair)

American Academy of Microbiology, Board of Governors

National Cancer Institute Board of Scientific Counselors (Chair)

NIH Advisory Board for Clinical Research (Chair)

Infectious Diseases Society of America (President)

Antibiotics in early life alter the murine colonic microbiome and adiposity., Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences., Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice., The Past and Future Biology of the Human Microbiome in an Age of Extinctions., Antibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunity., Preserving microbial diversity., Long-Term Effects of Early-Life Antibiotic Exposure on Resistance to Subsequent Bacterial Infection., Maternal cecal microbiota transfer rescues early-life antibiotic-induced enhancement of type 1 diabetes in mice., Effects of early-life penicillin exposure on the gut microbiome and frontal cortex and amygdala gene expression., An Antibiotic-Impacted Microbiota Compromises the Development of Colonic Regulatory T Cells and Predisposes to Dysregulated Immune Responses., Association of Infant Antibiotic Exposure With Childhood Health Outcomes., Disruption of the early-life microbiota alters Peyer’s patch development and germinal center formation in gastrointestinal-associated lymphoid tissue, Denoising sparse microbial signals from single-cell sequencing of mammalian host tissues., Saliva microbiome in relation to SARS-CoV-2 infection in a prospective cohort of healthy US adults., Predicting COVID-19 prognosis in hospitalized patients based on early status, Alzheimer's Disease Has Its Origins in Early Life via a Perturbed Microbiome., Gut microbiota phospholipids regulate intestinal gene expression and can counteract the effects of antibiotic treatment